RxDoctor Payments Data

Diana Alanis, MD

Family Medicine · Rockford, ILNPI 1922007418

Payments from drug & device makers

$460in general payments, 2019–2025

Across 26 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$148
  • Lilly USA, LLC$72
  • Pfizer$65
  • Novo Nordisk$43
  • Orexo US, Inc.$41
  • Exact Sciences$36
  • plus $54 from 3 others
$125in research payments, 2019–2025

Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$125

What the payments were for

  • Food & beverage$44998%
  • Education$112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$460 in reported general payments places this provider in the 60th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$32,684
Medicare patients
101
Services billed
303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban29$32,902
OzempicSemaglutide17$23,571
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$18,855
EliquisApixaban20$15,157
JanuviaSitagliptin Phosphate14$13,397
Tresiba Flextouch U-100Insulin Degludec15$11,926
JardianceEmpagliflozin11$10,082
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen273$9,227
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$5,695
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,019
SymbicortBudesonide/Formoterol Fumarate11$3,203
Humalog Kwikpen U-100Insulin Lispro13$2,900
Gabapentin178$2,708
Pregabalin44$2,505
Diclofenac Sodium47$1,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$23,57117 claims
PfizerEliquis$65$15,15720 claims
MerckJanuvia$22$13,39714 claims
AstraZenecaSymbicort$148$3,20311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →